This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia

John H. Krystal, MD; John P. Seibyl, MD; Lawrence H. Price, MD; Scott W. Woods, MD; George R. Heninger, MD; George K. Aghajanian, MD; Dennis S. Charney, MD

Arch Gen Psychiatry. 1993;50(8):624-635.

Abstract
Objective
This study evaluated whether alterations in serotonin function in schizophrenic patients could be demonstrated by comparing the reactivity to a serotonin partial agonist, m-chlorophenylpiperazine (MCPP) in patients and healthy subjects. This study also assessed whether stimulation of serotonin receptors influenced the symptoms of schizophrenia.

Design
Double-blind randomized comparison of MCPP (0.1 mg/kg, intravenously, administered over 20 minutes) and placebo effects in patients and healthy subjects.

Setting
Department of Veterans Affairs Medical Center, West Haven, Conn.

Patients and Healthy Subjects
Fifteen healthy subjects recruited by public advertisement and 12 schizophrenic inpatients who had been neuroleptic free for at least 2 weeks prior to entry into the study.

Main Outcome Measures
The principal outcome variable was the positive symptoms of schizophrenia operationally defined as the sum of scores on the four key items for schizophrenia on the Brief Psychiatric Rating Scale and the Brief Psychiatric Rating Scale thought disorder factor. Anxiety was assessed with a clinician-rated visual analog scale and plasma hormone levels were measured.

Results
m-Chlorophenylpiperazine significantly increased the positive symptoms of schizophrenia in patients but not healthy subjects. Patients and healthy subjects exhibited anxiety increases of comparable magnitude following MCPP. However, patients had higher baseline levels of anxiety and exhibited more prolonged anxiogenic responses to MCPP. Anxiety elevations did not correlate with increases in the four key symptoms in patients. Patients exhibited lower baseline prolactin levels compared with healthy subjects, but the two groups did not differ in their prolactin, growth hormone, and cortisol responses to MCPP.

Conclusions
Schizophrenics, the only psychotic patient group studied to date, are the first patient group to exhibit propsychotic responses to MCPP. These data provide further evidence that sertonin systems modulate positive symptoms in some schizophrenic patients.

Author Affiliations
From the Schizophrenia Biological Research Center, Department of Psychiatry, Yale University School of Medicine, West Haven (Conn) Veterans Affairs Medical Center, (Drs Krystal, Seibyl, and Charney), and the Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven (Drs Krystal, Seibyl, Price, Woods, Heninger, Aghajanian, and Charney).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity
Marquis et al.
J. Pharmacol. Exp. Ther. 2007;320:486-496.
ABSTRACT | FULL TEXT  

The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
Roth et al.
Neuroscientist 2000;6:252-262.
ABSTRACT  

Serotonin 5-HT2 Receptors in Schizophrenia: A PET Study Using [18F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects
Lewis et al.
Am. J. Psychiatry 1999;156:72-78.
ABSTRACT | FULL TEXT  

Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder
Southwick et al.
Arch Gen Psychiatry 1997;54:749-758.
ABSTRACT  

Effect of Menstrual Cycle Phase on Neuroendocrine and Behavioral Responses to the Serotonin Agonist m-Chlorophenylpiperazine in Women with Premenstrual Syndrome and Controls
Su et al.
J. Clin. Endocrinol. Metab. 1997;82:1220-1228.
ABSTRACT | FULL TEXT  

Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal et al.
Arch Gen Psychiatry 1994;51:898-911.
ABSTRACT